Compounds useful for inhibiting metastasis from cancer and methods using same
The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.
1. A compound of Formula (I):
wherein:
A 1 is CH 2 ;
n is 0, 1, 2, 3, 4 or 5;
A 2 and A 3 are both H, or A 2 and A 3 combine to form a divalent radical selected from the group consisting of methanediyl, ethane-1,2-diyl, or propane-1,3-diyl;
A 4 is CH 2 ;
R 1 and R 2 are both H, and R 3 is
R 4 is nil;
R 7 is H or OH;
wherein:
(a) ring A is selected from the group consisting of phenyl and substituted phenyl, and R 5 is triazolyl, substituted triazolyl, 1,2-benzisoxazolyl or substituted 1,2-benzisoxazolyl; or
(b) ring A is selected from the group consisting of
and R 5 is phenyl, substituted phenyl, triazolyl, substituted triazolyl, 1,2-benzisoxazolyl, or substituted 1,2-benzisoxazolyl;
a pharmaceutically acceptable salt or solvate thereof, or any combinations thereof.
2. The compound of claim 1 , wherein in (b) R 5 is selected from the group consisting of phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, and 4-methoxyphenyl.
3. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , which is formulated for an administration route selected from the group consisting of inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, and any combinations thereof.